Literature DB >> 17033628

Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia.

K M R Prasad1, B H Shirts, R H Yolken, M S Keshavan, V L Nimgaonkar.   

Abstract

Infectious agents have been proposed as one of the risk factors for schizophrenia. However, the data on the association of infectious agents with in vivo brain changes are scant. We evaluated the association of serological evidence of exposure to herpes simplex virus 1 (HSV1) with in vivo brain structural variations among first-episode antipsychotic-naive schizophrenia/schizoaffective disorder patients and control subjects. We assayed HSV1 immunoglobulin G (IgG) antibody in serum samples from 30 patients and 44 healthy subjects and obtained structural magnetic resonance imaging scans from the same individuals. There were proportionately more patients with elevated HSV1 antibody ratios than healthy comparison subjects (chi2=3.98, 1 df, P=0.046) and patients had significantly higher HSV1 IgG antibody ratios compared with healthy subjects. Using optimized voxel-based morphometry, we examined diagnosis by HSV1 serological status interaction followed by within- and between-group comparison across the serological status. We observed a diagnosis by HSV1 serological status interaction and a significant main effect of HSV1 serological status in the prefrontal gray matter. Patients exposed to HSV1 had decreased gray matter in Brodmann area 9 (dorsolateral prefrontal cortex) and 32 (anterior cingulate cortex) compared with patients without serological evidence of exposure to HSV1. HSV1-associated differences in brain structure were not detected among healthy subjects. These findings suggest that HSV1 exposure in schizophrenia is associated with specific regional gray matter differences that may not be attributable to medications, illness chronicity or comorbid substance use. This study provides suggestive evidence for a link between HSV1 exposure and some of the cerebral morphological changes often reported in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033628     DOI: 10.1038/sj.mp.4001915

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  28 in total

1.  Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study.

Authors:  Konasale M Prasad; Shaun M Eack; Dhruman Goradia; Krishna M Pancholi; Matcheri S Keshavan; Robert H Yolken; Vishwajit L Nimgaonkar
Journal:  Am J Psychiatry       Date:  2011-06-01       Impact factor: 18.112

Review 2.  Structural cerebral variations as useful endophenotypes in schizophrenia: do they help construct "extended endophenotypes"?

Authors:  Konasale M Prasad; Matcheri S Keshavan
Journal:  Schizophr Bull       Date:  2008-04-11       Impact factor: 9.306

Review 3.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

4.  Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia.

Authors:  Brian H Shirts; Konasale M Prasad; Michael F Pogue-Geile; Faith Dickerson; Robert H Yolken; Vishwajit L Nimgaonkar
Journal:  Schizophr Res       Date:  2008-09-17       Impact factor: 4.939

5.  Classification of schizophrenia using feature-based morphometry.

Authors:  U Castellani; E Rossato; V Murino; M Bellani; G Rambaldelli; C Perlini; L Tomelleri; M Tansella; P Brambilla
Journal:  J Neural Transm (Vienna)       Date:  2011-09-09       Impact factor: 3.575

6.  Association of cognitive function and liability to addiction with childhood herpesvirus infections: A prospective cohort study.

Authors:  Michael M Vanyukov; Vishwajit L Nimgaonkar; Levent Kirisci; Galina P Kirillova; Maureen D Reynolds; Konasale Prasad; Ralph E Tarter; Robert H Yolken
Journal:  Dev Psychopathol       Date:  2017-04-19

7.  Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial.

Authors:  Konasale M Prasad; Shaun M Eack; Matcheri S Keshavan; Robert H Yolken; Satish Iyengar; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2012-03-23       Impact factor: 9.306

8.  Structural abnormalities in the cuneus associated with Herpes Simplex Virus (type 1) infection in people at ultra high risk of developing psychosis.

Authors:  Thomas J Whitford; Stephen J Wood; Alison Yung; Luca Cocchi; Gregor Berger; Martha E Shenton; Marek Kubicki; Lisa Phillips; Dennis Velakoulis; Robert H Yolken; Christos Pantelis; Patrick McGorry; G Paul Amminger
Journal:  Schizophr Res       Date:  2012-01-12       Impact factor: 4.939

9.  Are Bipolar Disorder and Schizophrenia Neuroanatomically Distinct? An Anatomical Likelihood Meta-analysis.

Authors:  Kevin Yu; Charlton Cheung; Meikei Leung; Qi Li; Siew Chua; Gráinne McAlonan
Journal:  Front Hum Neurosci       Date:  2010-10-26       Impact factor: 3.169

10.  Systematic association studies of mitochondrial DNA variations in schizophrenia: focus on the ND5 gene.

Authors:  Mikhil N Bamne; Michael E Talkowski; Carlos T Moraes; Stephen B Manuck; Robert E Ferrell; Kodavali V Chowdari; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2007-09-26       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.